Related Topics News -

     
 Title only   |   Print    Next page > 
     
三生製藥上周五回購250萬股 涉資近3,759萬元

2026-10-12T  
三生製藥昨斥2,650萬元回購170萬股

2026-10-09T  
《大行》摩通:美國財政部或容許大部分中國醫藥對外授權交易 正關注「COINS法案」措辭

2026-09-22T  
《大行》美銀證券:中國醫療保健行業加快創新及全球化 中生製藥目標價升至7.3元

2026-09-21T  
《大行》瑞銀:中國製藥股上半年業績好壞參半 首選先聲藥業

2026-09-09T  
《大行》里昂降三生製藥目標價至30.4元 維持「跑贏大市」評級

2026-08-31T  
《大行》中金降三生製藥目標價18%至30元兼下調盈測 上半年業績符預期

2026-08-25T  
《大行》招銀國際微降三生製藥目標價至34.78元 重申「買入」評級

2026-08-25T  
《大行》花旗降三生製藥目標價至34.4元 行業反腐影響預測下調

2026-08-24T  
《業績》三生製藥中期純利11.47億人民幣 倒退15.6%

2026-08-21T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.